Treatment Of Macular Degeneration With Complement Factor D (CFD) Inhibitors
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsNeelroop Parikshak, Eric Jorgenson, Xinyuan Zhang, Giovanni Coppola, Goncalo Abecasis, Aris Baras, Botir Sagdullaev, Ying Hu, Kevin Kanning, Aarin Jones, Huy Vu
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to the treatment of subjects having macular degeneration or at risk of developing macular degeneration by administering a Complement Factor D (CFD) inhibitor to the subject, and to methods of identifying subjects having an increased risk of developing macular degeneration.
Claims44
A method of treating a subject having macular degeneration or at risk of developing macular degeneration, the method comprising administering a Complement Factor D (CFD) inhibitor to the subject.
A method of treating a subject having macular degeneration or at risk of developing macular degeneration by administering a macular degeneration therapeutic agent or macular degeneration therapy, the method comprising:
- determining or having determined whether the subject has a Complement Factor D (CFD) variant nucleic acid molecule, by:
- obtaining or having obtained a biological sample from the subject;
- and
- performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising a CFD variant nucleic acid molecule;
- and
- administering or continuing to administer the macular degeneration therapeutic agent in an amount that is the same as or less than a standard dosage amount or macular degeneration therapy, and/or a CFD inhibitor to a subject that is CFD reference;
- administering or continuing to administer the macular degeneration therapeutic agent in an amount that is the same as or less than a standard dosage amount or macular degeneration therapy, and/or a CFD inhibitor to a subject that is heterozygous for the CFD variant nucleic acid molecule;
- or
- administering or continuing to administer the macular degeneration therapeutic agent in a standard dosage amount or macular degeneration therapy to a subject that is homozygous for the CFD variant nucleic acid molecule;
- wherein the presence of the CFD variant nucleic acid molecule indicates the subject has a decreased risk of developing macular degeneration.
A method of identifying a subject having an increased risk of developing macular degeneration, the method comprising:
- determining or having determined the presence or absence of a Complement Factor D (CFD) variant nucleic acid molecule in a biological sample obtained from the subject;
- wherein:
- when the subject is CFD reference, then the subject has an increased risk of developing macular degeneration;
- and
- when the subject is heterozygous or homozygous for the CFD variant nucleic acid molecule, then the subject has a decreased risk of developing macular degeneration.
A macular degeneration therapeutic agent for use in the treatment or prevention of macular degeneration in a subject having a Complement Factor D (CFD) variant nucleic acid molecule.
A Complement Factor D (CFD) inhibitor for use in the treatment or prevention of macular degeneration in a subject that is CFD reference or is heterozygous for a CFD variant nucleic acid molecule.
Dependencies are inferred from the claim text.